Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.

ABSTRACT: This a Phase III trial designed to determine if IV casopitant plus dexamethasone and ondansetron is more effective in the prevention of vomiting and nausea then dexamethasone and ondansetrone alone following the administration of moderately emetogenic oxaliplatin-based chemotherapy.

DISEASE(S): Prevention Of Nausea And Vomiting Due To First Cycle Of Oxaliplatin Based Chemotherapy In Patients With Colorectal Cancer Receiving A Combination With 5-fluorouracil And Leucovorin, Or In Combination With Capecitabine.,Nausea And Vomiting, Chemotherapy-induced,Vomiting,Colorectal Cancer,Nausea

PROVIDER: 2049587 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer

Project description:Addition of aprepitant, an NK1 receptor antagonist to a 5-HT3 receptor antagonist and dexamethasone regimen was shown to be effective for prevention of chemotherapy-induced nausea and vomiting (CINV) with moderately emetogenic chemotherapy (MEC). Little is known about the efficacy of aprepitant when used without dexamethasone. Dexamethasone is widely used to prevent both acute and delayed nausea and vomiting induced by chemotherapy. However, multi-period use of dexamethasone could be associated with side effect, such as hyperglycemia, dyspepsia and insomnia. This randomized phase III trial studies antiemetic therapy with aprepitant and tropisetron to see how well they work compared to dexamethasone plus tropisetron in preventing chemotherapy-induced nausea and vomiting in patients with colorectal cancer receiving FOLFOX(oxaliplatin, leuvovorin and 5-fluorouracil) chemotherapy.

| 2225674 | ecrin-mdr-crc

A randomized, multicenter non-inferiority trial of 1-day versus 3-day dexamethasone in combination with palonosetron for prevention of nausea and vomiting induced by moderately emetogenic chemotherapy

Project description:Interventions: dexamethasone day1-3 plus palonosetron dexamethasone day1 plus palonosetron Primary outcome(s): Percentage of patients with complete response (no vomiting and no rescue medication) during day1-5 after moderately emetogenic chemotherapy Study Design: Parallel Randomized

| 2624800 | ecrin-mdr-crc

Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial

Project description:The object of this study is to evaluate the superiority of aprepitant therapy with a 5HT3-receptor antagonist, dexamethasone and aprepitant compared to standard therapy with a 5HT3-receptor antagonist and dexamethasone for prevention of nausea and vomiting in first course chemotherapy.

| 2105952 | ecrin-mdr-crc

Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment

Project description:RATIONALE: Antiemetic drugs, such as ondansetron, may help to reduce or prevent nausea and vomiting in patients with advanced cancer. PURPOSE: This randomized phase III trial is studying how well ondansetron works compared to a placebo in treating patients with advanced cancer and chronic nausea and vomiting that is not caused by cancer therapy.

| 2005380 | ecrin-mdr-crc

Effect of gabapentin capsules on nausea and vomiting

Project description:Intervention 1: In the intervention group: gabapentin capsule of 300 milligrams three times a day from one day Chemotherapy will be used until the end of the chemotherapy period. Intervention 2: In the control group, for the reduction of nausea and vomiting after chemotherapy, a routine of three drugs (dexamethasone, ranitidine and ketril) will be used.;Treatment - Drugs;Treatment - Drugs;In the intervention group: gabapentin capsule of 300 milligrams three times a day from one day Chemotherapy will be used until the end of the chemotherapy period.;In the control group, for the reduction of nausea and vomiting after chemotherapy, a routine of three drugs (dexamethasone, ranitidine and ketril) will be used Primary outcome(s): Nausea and vomiting. Timepoint: after intervention. Method of measurement: By grade. Study Design: Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment.

| 2493651 | ecrin-mdr-crc

Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen

Project description:RATIONALE: Antiemetic drugs may help to reduce or prevent vomiting in patients treated with radiation therapy. It is not yet known if ondansetron is more effective with or without dexamethasone in preventing vomiting caused by radiation therapy. PURPOSE: This randomized phase III trial is comparing how well ondansetron works with or without dexamethasone in preventing vomiting in patients with cancer who are receiving radiation therapy to the upper abdomen.

| 2006187 | ecrin-mdr-crc

Nk-1 receptor antagonist, 5-ht3 receptor antagonist and dexamethasone antiemetic regimen to prevent nausea and vomiting induced by chemotherapy drugs with high emetic risk for several days

Project description:Interventions: single arm:Nk-1 receptor antagonist, 5-ht3 receptor antagonist and dexamethasone antiemetic regimen Primary outcome(s): According to the international evaluation system for adverse reactions to chemotherapy drugs (CTCAE) version 4.03. Nausea is defined as a condition characterized by nausea and/or an urgent need for vomiting.;Complete remission rate (CR): number of CINV complete remission patients/number of chemotherapy patients x100%; CINV complete remission was defined as (CTCAE) version 4.03, nausea and vomiting grade 0 (no nausea and vomiting).;Adverse reactions: adverse events and laboratory tests were graded according to NCI CTC AE 4.0, and special attention should be paid to early withdrawal from the study as well as vital signs (such as blood pressure, body temperature, etc.), intestinal obstruction, intractable hiccups, uncontrollable headaches, etc. Study Design: Single arm

| 2685822 | ecrin-mdr-crc

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.

Project description:BackgroundWe examined the efficacy of olanzapine for the prevention of nausea and vomiting in patients receiving highly emetogenic chemotherapy.MethodsIn a randomized, double-blind, phase 3 trial, we compared olanzapine with placebo, in combination with dexamethasone, aprepitant or fosaprepitant, and a 5-hydroxytryptamine type 3-receptor antagonist, in patients with no previous chemotherapy who were receiving cisplatin (≥70 mg per square meter of body-surface area) or cyclophosphamide-doxorubicin. The doses of the three concomitant drugs administered before and after chemotherapy were similar in the two groups. The two groups received either 10 mg of olanzapine orally or matching placebo daily on days 1 through 4. Nausea prevention was the primary end point; a complete response (no emesis and no use of rescue medication) was a secondary end point.ResultsIn the analysis, we included 380 patients who could be evaluated (192 assigned to olanzapine, and 188 to placebo). The proportion of patients with no chemotherapy-induced nausea was significantly greater with olanzapine than with placebo in the first 24 hours after chemotherapy (74% vs. 45%, P=0.002), the period from 25 to 120 hours after chemotherapy (42% vs. 25%, P=0.002), and the overall 120-hour period (37% vs. 22%, P=0.002). The complete-response rate was also significantly increased with olanzapine during the three periods: 86% versus 65% (P<0.001), 67% versus 52% (P=0.007), and 64% versus 41% (P<0.001), respectively. Although there were no grade 5 toxic effects, some patients receiving olanzapine had increased sedation (severe in 5%) on day 2.ConclusionsOlanzapine, as compared with placebo, significantly improved nausea prevention, as well as the complete-response rate, among previously untreated patients who were receiving highly emetogenic chemotherapy. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT02116530.).

| S-EPMC5344450 | biostudies-literature

Delayed Nausea and Vomiting in Patients With Colorectal Cancer Receiving Oxaliplatin

Project description:RATIONALE: Learning how often patients experience nausea and vomiting after receiving anti-vomiting medicine and chemotherapy for colorectal cancer may help doctors plan better treatment and improve patients’ quality of life. PURPOSE: This clinical trial is studying delayed nausea and vomiting in patients with colorectal cancer receiving standard anti-vomiting medicine during the first course of chemotherapy.

| 2059306 | ecrin-mdr-crc

Area postrema cell types that mediate nausea-associated behaviors

Project description:Nausea, the unpleasant sensation of visceral malaise, remains a mysterious process. The area postrema is implicated in some nausea responses, and contains poorly understood brain-resident sensory neurons that are anatomically privileged to detect bloodborne signals. To investigate nausea mechanisms, we built an area postrema cell atlas through single-nucleus RNA sequencing, revealing a few neuron types. Using mouse genetic tools for cell-specific manipulation, we discovered excitatory neurons that induce nausea-related behaviors, with one neuron type mediating aversion imposed by multiple poisons. Nausea-associated responses were observed to agonists of identified area postrema receptors, and suppressed by targeted cell ablation and/or gene knockout. Anatomical mapping revealed a distributed network of long-range excitatory but not inhibitory projections with subtype-specific patterning. These studies reveal the basic organization of area postrema nausea circuitry, and provide a framework towards understanding and therapeutically controlling nausea.

2020-12-07 | GSE160938 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data